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R755to form multiple colour spaces?
Perhaps the outputs are used for
detection of targets having a specific
spectral reflectance that can be
compared to a ‘search image’ leading
to a behavioural response as
suggested by Thoen et al. [12]. What is
needed are more data about the neural
‘analytical engine’ employed by the
shrimp to extract useful information
from the receptor outputs. Even
without this, behavioural experiments
can be designed to elucidate the
functional significance of specific UV
patterns within the 300 nm to 400 nm
range. One must not overlook the
possibility that the information from the
UV channels is somehow integrated
with that from the other spectral
channels or even the polarization
channels to release specific
behaviours. Even with all that is
known about these fascinating
animals, there is still a plethora of
information to be gleaned from mantis
shrimp that may lead to new ways of
analyzing the visual world and
identifying those targets within it of
adaptive significance.From the point of view of the
observer, it would also be useful to
obtain hyperspectral images of the
visual world of mantis shrimps with
the kind of spectral resolution and
bandwidth found in the shrimps. What
is there to ‘see’ in the UV between
300 nmand 400 nm that wouldmake six
separate spectral channels adaptive?
There may be secrets in the UV visual
‘world’ of themarine environment yet to
be discovered.
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SchizophreniaNew studies have substantially advanced our understanding of the genetic
architecture of schizophrenia, but we are far from identifying the underlying
mutations. We may require new approaches to understand the biological
implications of insights into the genetics of psychiatric disease.Jonathan Flint1,*
and Marcus R. Munafo`2
There is a view that genome-wide
association studies (GWAS) have not
been particularly helpful when applied
to psychiatric diseases. It’s true, the
score-card is remarkably patchy: for
the commonest condition, major
depression, which ranks among the top
three causes of morbidity world-wide
[1], there are no agreed loci that
contribute to disease risk, while for
schizophrenia there are now 108 [2], a
far higher score than for many other
diseases. Differences in genetic
architecture (that is, the number of loci
involved and their individual effect
sizes) explains the disparity in
success rates: it’s estimated thatfinding one locus contributing to major
depression will require a case-control
study with more than 50,000 cases [3],
whilst the first findings for
schizophrenia emerged when 9,000
cases were genotyped [4]. Why
genetic architecture differs so
much between diseases is not clear,
but the consequences are unarguable:
genetic dissection of inflammatory
bowel disease required only a few
thousand cases [5], whereas
genetic dissection of hypertension
required tens of thousands [6].
Three new studies [2,7,8] throw new
light on the genetic basis of
schizophrenia with implications for our
understanding of the genetic
architecture of psychiatric
disease (Figure 1).From Genetics to Biological Insight
The commonly held justification for
carrying out (expensive) GWAS of
disease is that the mapping studies
take the first steps towards the
identification of genes, from which will
proceed novel insights into disease
pathogenesis. Nowhere is this more
needed than for psychiatric diseases,
where the underlying biology remains
shrouded in mystery. One hope was
that sequencing genes near or at
GWAS loci would prove a gene’s
candidacy: finding individuals with
the disease who carried deleterious
mutations would unequivocally show
that the mutated gene was involved
in the disease (although this would
not identify the sequence variants
responsible for the GWAS signal).
This argument assumed that in some
people disease is due to large effect
mutations. Successful sequencing of
exomes at loci contributing to type 1
diabetes [9] and Crohn’s disease [10]
gave some credence to the view that
causal mutations could be found for
complex disease.
For schizophrenia, the advent of
population-scale sequencing opened
Figure 1. A complex picture.
Drawing entitled ‘Irren-Anstalt Band-Hain’ by artist Adolf Wo¨lfli (1864–1930), who was diag-
nosed with schizophrenia and spent the last 35 years of his life in a Swiss institution.
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number of exomes and looking for the
tell-tale signatures of DNA variants
that inactivate genes. In particular,
mutations found in a proband (the
affected individual), but not in his or her
unaffected parents (thus de novo
mutations), appear to provide good
evidence for a gene’s causal role. A few
years ago, the first exome studies of
schizophrenia indicated that such
mutations existed. One study identified
15 de novo mutations, four of which
were reported as nonsense mutations,
from sequencing just 14 schizophrenia
families [11]. The other identified 40
de novomutations in 27 cases [12]. The
following year, from sequencing 231
affected families, the number of
loss-of-function events was found to
be 2.8 times higher than in control
family trios (8.7% compared to 2.9%)
[13]. It seemed only a matter of time
before unambiguous, highly penetrant
mutations would be found, and the
long-sought entrance into the biology
of schizophrenia finally revealed.
Earlier this year two papers [7,8]
described the largest exome
sequencing studies yet attempted for
schizophrenia, one reporting results for
2,536 cases and 2,543 controls [8], the
other for 623 trios (two parents and one
affected offspring) [7]. Even though the
first study reports data from only 2,500
genes (about 10% of the genome), thisis still an enormous advance. Yet, the
authors of neither study go so far as to
give us the names of genes that they
regard as unequivocally implicated by
highly penetrant mutations. Indeed the
second paper (the 623 trios) fails to
confirm an enrichment of de novo
mutations in cases of schizophrenia.
Enrichment is found, but only when
analysis is restricted to sets of
candidate genes (which is also true
of the first paper, with its focus on
2,500 genes that were implicated by
previous findings). What is going on
here? Why don’t we have a
schizophrenia gene yet?
The short answer is that it is still not
clear what the ground rules are. In fact,
this discussion touches on a deep
divide, between those who think
biologically, and those who think
statistically. We’ll caricature the two
positions, just to make the distinction
between them obvious.
Biology and Statistics
Biologically speaking, finding a
mutation that has a barn-door obvious
effect, such as something that stops
transcription in its tracks, needs no
statistical justification. This position
holds that mutations ablating two
copies of a gene will (almost) always
have a phenotype. Whether a single
mutation has a noticeable effect
depends on whether the cell canfunction with half the usual amount of
functional protein. The bottom line is
that, without worrying unduly why this
might be so, finding inactivating
mutations is a great way to get a handle
on the biology of a phenotype. There
are many instances where the
approach has worked, leading to new
insights into basic biological
processes [14,15].
The alternative standpoint,
statistically speaking this time, holds
that an unbiased screen for genetic
mutations should be just that — reliant
solely on the statistical evidence for
association, unsullied by any post hoc
justifications. Statistical rigour is
one reason why GWAS have been
successful — GWAS users deploy a
single statistical threshold to declare
significance for association between
a sequence variant and phenotype
(P < 53 1028). Most of the variants that
achieve this threshold are replicable
and robust. There is a degree of
frustration that the same is not
happening with sequence analysis.
In a commentary published this year,
there is a complaint that ‘‘investigators
should not simply assume that the
presence of two or more independently
occurring de novo mutations in the
same gene within a sequenced cohort
is definitive evidence of a causal role for
that gene; such a threshold results in
ever increasing numbers of false
positives as the number of sequenced
cases increases’’ [16]. The
recommendation is to adopt ‘‘a
conservative genome-wide
significance threshold corresponding
to this testing strategy is a Bonferroni-
corrected P value of 1.73 1026 (that is,
0.05 out of 30,000)’’.
Which approach is correct here? To
many human geneticists, one of the
surprises of 2012 was the report that a
healthy genome contains about one
hundred loss of function variants (i.e.,
mutations predicted to abrogate gene
function). Every one of us carries
mutations that inactivate both copies of
approximately twenty genes [17]. The
explanation for why these mutations
are found in people who, to all intents
and purposes, are perfectly healthy, is
almost certainly the presence of other
genetic variants that compensate for
the loss of gene function. Any scientist
working with inbred organisms knows
how much genetic background
influences phenotypes associated with
a mutation. Genetic background can
determine whether a mutation has no
Dispatch
R757phenotype, or whether it acts in a
dominant or recessive fashion. The
recent systematic analysis of mouse
knockouts (complete abrogation of
gene function) reports that 35% (56 of
160) appeared completely normal [18].
In other words, even with the
application of rigorous criteria to define
a highly deleterious mutation, we can
still find these supposedly pathogenic
mutations in healthy people. The
reluctance of schizophrenia
researchers to claim they have found
causal mutations is understandable.
Just what will it take to get to the point
of declaring victory? The scale of the
problem is made clear in a recent
discovery of protein-altering variants in
SLC30A8, confirming that the gene is
involved in type 2 diabetes. Analysis of
about 150,000 individuals was needed
to secure the finding [19]. We are
nowhere near that number for
schizophrenia; indeed, it’s possible
we’ll never have the type of evidence
that we have for genes involved in
diabetes or inflammatory bowel
disease. The flexibility and adaptability
that is such a notable feature of human
behaviour brings a freedom from
genetic determination that presumably
extends to behaviour in illness. While
our understanding of the genetic
architecture of behaviour is too limited
to make definitive claims, there is a real
possibility that the sought after large
effect mutations may be of much
smaller effect than is hoped for. New
approaches may be needed to work up
the biological implications of our hard
won insights into the genetic basis of
psychiatric disease.References
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the Origin of NeuronsRecent sequencing of ctenophore genomes opens a new era in the study of this
uniqueandphylogeneticallydistantgroup.Thepresenceofneurodevelopmental
genes, pre- and postsynaptic modules, and transmitter molecules is consistent
with a single origin of neurons.Heather Marlow and Detlev Arendt
The origin of neurons and nervous
systems is one of the most exciting
questions in animal evolution. Neurons,
electrically excitable cells that signal
to target cells via synapses, arefound in three animal lineages: in the
bilaterians — comprising vertebrates,
insects, nematodes and other groups
often found with ganglia, nerve cords
and brains; in the cnidarians — polyps
and jellyfish with nerve nets that
cover the entire body; and in a thirdgroup that, until very recently, has
received little attention— the enigmatic
ctenophores, or ‘comb jellies’
(Figure 1A). The ctenophore nervous
system is a nerve net (Figure 1B) with
local aggregations of neurons, most
pronounced around the apex of the
animal [1,2] (Figure 1C). As the
gelatinous body of the ctenophores
resembles that of cnidarian jellyfish,
many authors assumed that cnidarians
and ctenophores are related (grouped
as ‘coelenterates’ [3]). Yet, this viewhas
been challenged by the very different
way these animals move: while
rhythmic muscle contractions propel
the cnidarianmedusae, the comb jellies
